# PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care

> **NCT05468203** · PHASE3 · TERMINATED · sponsor: **The George Institute** · enrollment: 51 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05468203
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-29
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-12-23
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** The vanguard phase is complete. Further phases did not proceed due to funding constraints. A revised methodology is planned, requiring a new protocol and approvals.
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468203, "PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05468203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*